METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION
    12.
    发明申请
    METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION 审中-公开
    治疗肺动脉高压的方法

    公开(公告)号:US20100144886A1

    公开(公告)日:2010-06-10

    申请号:US12710133

    申请日:2010-02-22

    CPC分类号: A61K31/277

    摘要: The present invention is directed to methods comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats, prevents and/or manages at least one condition having MT1 receptor, 5-HT2B receptor and L-type calcium channel activity and releases the (R)-verapamil, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a co-primary activity on the MT1 receptor, the 5-HT2B receptor, and the L-type calcium channel.

    摘要翻译: 本发明涉及包括施用包含治疗有效量的(R) - 维拉帕米,其衍生物或其药学上可接受的盐的组合物的组合物,其中所述组合物治疗,预防和/或控制至少一种具有MT1 受体,5-HT2B受体和L-型钙通道活性,并释放(R) - 维拉帕米,其衍生物或其药学上可接受的盐,以在MT1受体,5-HT2B受体和 L型钙通道。

    Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity
    13.
    发明申请
    Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity 审中-公开
    用于治疗至少一种具有MT1受体,5HT2B受体和L型钙通道活性的病症的方法

    公开(公告)号:US20080045603A1

    公开(公告)日:2008-02-21

    申请号:US11826804

    申请日:2007-07-18

    CPC分类号: A61K31/277

    摘要: The present invention is directed to methods comprising administering a composition comprising a therapeutically effective amount of (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats, prevents and/or manages at least one condition having MT1 receptor, 5-HT2B receptor and L-type calcium channel activity and releases the (R)-verapamil, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a co-primary activity on the MT1 receptor, the 5-HT2B receptor, and the L-type calcium channel.

    摘要翻译: 本发明涉及包括施用包含治疗有效量的(R) - 维拉帕米,其衍生物或其药学上可接受的盐的组合物的组合物,其中所述组合物治疗,预防和/或控制至少一种具有MT1 受体,5-HT2B受体和L-型钙通道活性,并释放(R) - 维拉帕米,其衍生物或其药学上可接受的盐,以在MT1受体上显示共同活性, 2B受体和L型钙通道。

    Identification of genes having a role in the presentation of diabetic nephropathy
    15.
    发明授权
    Identification of genes having a role in the presentation of diabetic nephropathy 失效
    鉴定在糖尿病肾病呈现中具有作用的基因

    公开(公告)号:US07052865B1

    公开(公告)日:2006-05-30

    申请号:US09914191

    申请日:2000-02-28

    IPC分类号: C12Q1/00 C12Q1/02 C07H21/04

    CPC分类号: C12Q1/6809

    摘要: A method for identifying a gene having a role in the presentation of diabetic nephropathy comprises culturing mesangial cells in the presence of a concentration of glucose sufficient to induce differential expression, especially up-regulation, of a gene susceptible to such differential expression and identifying the gene so induced. The cells are also optionally subjected to mechanical strain and/or TGF-β1 can be added to the culture medium. The differentially expressed genes can be identified by suppression subtractive hybridisation. The method has resulted in the Identification of novel genes which play a role in the presentation of diabetic nephropathy. The genes can be used as diagnostic markers for diabetic nephropathy and as the basis of drug development programmes.

    摘要翻译: 用于鉴定在糖尿病肾病呈现中具有作用的基因的方法包括在足以诱导对这种差异表达敏感的基因的差异表达,特别是上调的葡萄糖浓度存在下培养肾小球系膜细胞,并鉴定该基因 所以诱导。 细胞还任选地受到机械应变,和/或可以将TGF-β1加入到培养基中。 差异表达的基因可以通过抑制消减杂交鉴定。 该方法导致了鉴定在糖尿病肾病呈现中发挥作用的新基因。 该基因可用作糖尿病肾病的诊断标志物,并作为药物开发方案的基础。

    Pet casket
    16.
    外观设计

    公开(公告)号:USD341915S

    公开(公告)日:1993-11-30

    申请号:US735459

    申请日:1991-07-25

    申请人: Mary Martin

    设计人: Mary Martin